The Food and Drug Administration delayed its decision on approving Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy until June 22. Sarepta noted that the agency is also “working toward potentially granting an accelerated approval” for the drug, SRP-9001. (STAT News)
A paralyzed man was able to walk naturally again with brain and spine implants, researchers reported. In a recent study, researchers describe a device that connects the intentions of a paralyzed patient to his physical movements. (The New York Times)
Eloxx Pharmaceuticals said it plans to move its lead candidate, ELX-02, into a Phase 3 clinical trial for rare disease Alport syndrome with nonsense mutations. Topline Phase 2 data on the drug showed one of three patients was able to achieve remission. (Endpoints News)
A daily multivitamin may help slow memory loss in people ages 60 and older, a large nationwide clinical trial suggested. The most recent study found that those taking multivitamins showed an estimated 3.1 fewer years of memory loss compared with a control group who took a placebo. (The Washington Post)
Purdue Pharma received a bankruptcy judge’s permission to sell its consumer health business for $397 million to a subsidiary of Arcadia Consumer Healthcare. Purdue’s creditors’ committee has pushed the company to use the proceeds from the sale to get started on that effort by compensating victims of the opioid crisis and funding addiction treatment programs. (Reuters)
